An interventional study of Molecular studies in Chondrosarcoma, sponsored by Istituto Ortopedico Rizzoli. Active, not recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Istituto Ortopedico Rizzoli · Not applicable, Interventional, and Other
Clear cell chondrosarcoma of bone is considered a low-grade malignant tumor in the last WHO classification of soft tissue and bone tumors; however, it is reported that recurrences and metastasis can occur. Considering the uncertain prognosis of this rare tumor, with some cases that historically seems to pursue a bad prognosis, we decided to collect all the Italian cases of clear cell condrosarcoma, in order to better understand its natural history and prognosis.
99 studies on the registry are indexed under Chondrosarcoma; 20 are open to participants now.
This study's enrollment of 77 is above the median of 52 across 72 interventional studies indexed under Chondrosarcoma.
Browse Chondrosarcoma studies →Istituto Ortopedico Rizzoli is the lead sponsor of 304 studies on the registry; 103 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with a diagnosis of clear cell chondrosarcoma
Genetic: Molecular studies
Molecolar studies to define possible prognostic parameters
Prognostic accuracy
Ability of the model to predict overall survival, measured by AUC/C-index
Time frame: At baseline
Plan to share: Undecided
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.